Showing 911-920 of 1614 results for "".
- Zeiss to Showcase New Digital Technologies at ASCRShttps://modernod.com/news/zeiss-to-showcase-new-digital-technologies-at-ascrs/2482742/Zeiss Medical Technology will celebrate the adoption of digital cataract solutions and showcase newly available refractive treatment technology at the American Society of Cataract and Refractive Surgery (ASCRS) conference from April 25–27 in Los Angeles. Zeiss marks a ma
- China’s First IGF-1R Monoclonal Antibody Approved, Innovent Biologics Announceshttps://modernod.com/news/chinas-first-igf-1r-monoclonal-antibody-approved-innovent-biologics-announces/2482701/Innovent Biologics announced China’s approval of SYCUME® for thyroid eye disease (TED) earlier this week. SYCUME® is China’s first monoclonal antibody therapeutic option for TED and only the second available globally – marking the first new treatment
- Kala Bio Announces Chief Executive Officer Transitionhttps://modernod.com/news/kala-bio-announces-chief-executive-officer-transition/2482662/Kala Bio announced the resignation of Chief Executive Officer Mark Iwicki, and the appointment of Todd Bazemore, Kala's President and Chief Operating Officer, as interim CEO, effective immediately. Mr. Iwicki will continue to serve as Chair of the Board of Directors of Kala fol
- Lumenis Launches OptiLIFT, Device to Address Lower Lid Laxity and Impaired Blinkinghttps://modernod.com/news/lumenis-launces-optilift-device-to-address-lower-lid-laxity-and-impaired-blinking/2482652/Lumenis announced the launch of OptiLIFT, a new device that uses Dynamic Muscle Stimulation technology (DMSt) to tone facial muscles to improve lower lid laxity and impaired blinking. OptiLIFT marks one of the first treatment options that eliminates the need for surgery. “Op
- Iantrek Announces First Commercial Cases of C.Rex Micro-Interventional System for Trabecular Outflow Enhancementhttps://modernod.com/news/iantrek-announces-first-commercial-cases-of-crex-micro-interventional-system-for-trabecular-outflow-enhancement/2482640/Iantrek announced the completion of the first commercial cases utilizing its C.Rex micro-interventional system for canal outflow enhancement in glaucoma surgery. Iantrek said the milestone marks the beginning of the company's pre-launch activities for the C.Re
- Bausch + Lomb Launches enVista Aspire Monofocal and Toric IOLs in the European Unionhttps://modernod.com/news/bausch-lomb-launches-envista-aspire-monofocal-and-toric-iols-in-the-european-union/2482610/Bausch + Lomb announced the commercial launch of the enVista Aspire monofocal and toric IOLs in the European Union after receiving a CE Mark late last year. According to B+L, enVista Aspire combines 'intermediate optimized' optics, which are designed for a broader dept
- Outlook Therapeutics Receives NICE Recommendation of Lytenava for Wet AMDhttps://modernod.com/news/outlook-therapeutics-receives-nice-recommendation-for-lytenava-as-a-treatment-for-wet-amd/2482567/The UK’s National Institute for Health and Care Excellence (NICE) has recommended Lytenava (bevacizumab gamma) as an option for the treatment of wet AMD in adults. This marks the first positive reimbursement decision for Lytenava worldwide and supports its commercializat
- Cure Blindness Project Unveils Global Expansion Plan on World Sight Dayhttps://modernod.com/news/cure-blindness-project-unveils-global-expansion-plan-on-world-sight-day/2482471/In honor of World Sight Day on October 10, the non-profit Cure Blindness Project announced an expansion plan that will extend its sight-restoring services to six new countries: Burundi, Democratic Republic of the Congo, Liberia, Pakistan, Paraguay, and Zambia. This move marks the organi
- Rayner Announces First RayOne Galaxy Implantations in the UShttps://modernod.com/news/rayner-announces-first-rayone-galaxy-implantations-in-the-us/2482467/Rayner has announced the implantation of the first IOL in the RayOne Galaxy FDA-approved investigational device exemption (IDE) study. This milestone marks the beginning of a prospective, multicenter, randomized, masked, and active-controlled study aimed at evaluating the RayOne Galaxy
- Eyenovia Launches Clobetasol for Postoperative Ocular Surgery Pain and Inflammationhttps://modernod.com/news/eyenovia-launches-clobetasol-for-postoperative-ocular-surgery-pain-and-inflammation/2482460/Eyenovia announced the US launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05%, which is designed to address postoperative inflammation and pain following ocular surgeries. The FDA approval and launch marks the first new ophthalmic steroid to be a